Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30573546.
- Also identified by DOI 10.1126/science.aat9120 and PMC identifier 6420719.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In vaccine design, antigens are often arrayed in a multivalent nanoparticle form, but in vivo mechanisms underlying the enhanced immunity elicited by such vaccines remain poorly understood. We compared the fates of two different heavily glycosylated HIV antigens, a gp120-derived mini-protein and a large, stabilized envelope trimer, in protein nanoparticle or "free" forms after primary immunization. Unlike monomeric antigens, nanoparticles were rapidly shuttled to the follicular dendritic cell (FDC) network and then concentrated in germinal centers in a complement-, mannose-binding lectin (MBL)-, and immunogen glycan-dependent manner. Loss of FDC localization in MBL-deficient mice or via immunogen deglycosylation significantly affected antibody responses. These findings identify an innate immune-mediated recognition pathway promoting antibody responses to particulate antigens, with broad implications for humoral immunity and vaccine design.
Medical subject headings
- AIDS Vaccines
- Antibody Formation
- Germinal Center
- HIV Envelope Protein gp120
- HIV Infections
- Immunity, Innate
- Polysaccharides